Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERAP2 | Q6P179 | 2/20 | 0.58 |
| ▸ | LNPEP | Q9UIQ6 | 2/20 | 0.58 |
| ▸ | GNPAT | O15228 | 1/20 | 0.54 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.53 |
| ▸ | MMP2 | P08253 | 1/20 | 0.51 |
| ▸ | OPRD1 | P41143 | 5/20 | 0.50 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.50 |
| ▸ | REN | P00797 | 1/20 | 0.49 |
| ▸ | ECE1 | P42892 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29350734 | 1.00 | ERAP2 (0.58) | ERAP2LNPEPGNPATOPRK1MMP2 | |
| SCHEMBL31181266 | 0.97 | GNPAT (0.59) | ERAP2LNPEPGNPATOPRK1OPRD1 | |
| SCHEMBL30497071 | 0.96 | GNPAT (0.58) | ERAP2LNPEPGNPATOPRK1OPRD1 | |
| SCHEMBL30407529 | 0.93 | OPRK1 (0.56) | ERAP2LNPEPGNPATOPRK1OPRD1 | |
| SCHEMBL170652 | 0.93 | ERAP2 (0.65) | ERAP2LNPEPGNPATOPRK1MMP2 | |
| SCHEMBL1711485 | 0.93 | ERAP2 (0.65) | ERAP2LNPEPGNPATOPRK1MMP2 | |
| SCHEMBL28540087 | 0.93 | ERAP2 (0.65) | ERAP2LNPEPGNPATOPRK1MMP2 | |
| SCHEMBL29372662 | 0.93 | ERAP2 (0.65) | ERAP2LNPEPGNPATOPRK1MMP2 | |
| SCHEMBL29382413 | 0.93 | ERAP2 (0.65) | ERAP2LNPEPGNPATOPRK1MMP2 | |
| SCHEMBL9747671 | 0.93 | ERAP2 (0.65) | ERAP2LNPEPGNPATOPRK1MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025078919-A1 | TOPICAL COMPOSITION | Exalya S.r.l. (IT) | 2025-04-17 | — | — | WO | disclosed |